Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL) announced that CEO James Porter, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:00 a.m. PT in San Francisco.

A live webcast of the presentation will be available in the company's Investors section at www.nuvalent.com and the webcast will be archived for 30 days after the presentation.

News Market Reaction – NUVL

+1.85%

+1.85% Session close to close

In the Dec 22 session, NUVL gained 1.85%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Nuvalent’s participation in a major healthcare investor conference, off...

Analysis

This announcement highlights Nuvalent’s participation in a major healthcare investor conference, offering management a platform to discuss its clinical programs and recent regulatory and financing milestones. Against a backdrop of NDA progress and completed equity offerings, investors may focus on any qualitative updates shared at the event. Key factors to watch include clarity around commercialization plans, development timelines for lead kinase inhibitors, and how the company frames its cash runway and strategic priorities.

Key Figures

Conference time: 9:00 a.m. PT Webcast archive: 30 days

2 metrics

Conference time 9:00 a.m. PT Presentation at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Webcast archive 30 days Length of time conference webcast will remain available to investors

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 10	Board appointment	Positive	+0.2%	Appointment of experienced oncology executive Ron Squarer to Board of Directors.
Nov 26	Conference participation	Neutral	-0.7%	Management participation in Piper Sandler healthcare conference fireside chat webcast.
Nov 24	Equity offering close	Negative	+0.3%	Closing of public offering and full exercise of underwriters’ option by selling holders.
Nov 19	NDA acceptance	Positive	+0.8%	FDA acceptance of NDA for zidesamtinib in TKI pre-treated ROS1-positive NSCLC.
Nov 18	Equity offering pricing	Negative	-3.5%	Pricing of large public offering of Class A common stock for ~$500M gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent major events (NDA acceptance, equity offerings) produced modest but generally directionally consistent price reactions, while an offering close showed a slight divergence.

Recent Company History

Over the past months, Nuvalent reported several milestones including an NDA acceptance for zidesamtinib in ROS1-positive NSCLC on Nov 19, 2025 and sizeable equity offerings announced and priced on Nov 18–24, 2025. A board addition on Dec 10, 2025 and prior conference participation on Dec 4, 2025 rounded out news flow. Today’s J.P. Morgan conference appearance continues a pattern of investor-facing events alongside advancing late-stage oncology programs and recent capital raises.

Key Terms

kinase

1 terms

kinase medical

"creating precisely targeted therapies for clinically proven kinase targets in cancer"

A kinase is a type of enzyme that adds a small chemical tag (a phosphate) to other proteins, changing how they behave — like flipping a light switch to turn processes in a cell on or off. Kinases matter to investors because they are common drug targets in areas such as cancer, inflammation and metabolic disease; blocking or modifying a kinase can create a valuable therapy but also carries development and safety risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:00 a.m. PT in San Francisco. 

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302647193.html

SOURCE Nuvalent, Inc.

FAQ

When will Nuvalent (NUVL) present at the J.P. Morgan Healthcare Conference?

Nuvalent will present on January 13, 2026 at 9:00 a.m. PT.

Who will represent Nuvalent (NUVL) at the January 13, 2026 presentation?

CEO James Porter, Ph.D. will present on behalf of Nuvalent.

How can investors watch the Nuvalent (NUVL) presentation on January 13, 2026?

A live webcast will be available in the Investors section at www.nuvalent.com.

Will the Nuvalent (NUVL) webcast be available after the J.P. Morgan presentation?

Yes, the webcast will be archived for 30 days following the presentation.

What topics will Nuvalent (NUVL) likely cover at the J.P. Morgan presentation on January 13, 2026?

The presentation will cover the company’s clinical-stage programs and corporate updates as presented by the CEO.

Where is the 44th Annual J.P. Morgan Healthcare Conference presentation located for Nuvalent (NUVL)?

The presentation is scheduled in San Francisco with a simultaneous live webcast online.